Recombinant Mouse Anti-SARS-CoV S Antibody ( F26G19) (CAT#: PABW-114)

Figure 1 ELISA reactivity of mAbs with whole, inactivated SARS-CoV.

Hybridoma supernatants were tested at a 1:4 dilution in PBS + 0.2% BSA on pre-blocked plates, coated with 18 ng per well of inactivated, highly purified SARS-CoV. Positive clones were identified as having positive binding (color) in wells that were at least four-fold higher than the background level reactivity on BSA. Antigen legend: black bars—native, highly purified SARS-CoV; white bars—heat denatured, highly purified SARS-CoV; grey bars—BSA control.

Berry, J. D., Jones, S., Drebot, M. A., Andonov, A., Sabara, M., Yuan, X. Y., ... & Nicolas, B. (2004). Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus. Journal of virological methods, 120(1), 87-96.

Figure 2 Western immunoblot reactivity of mAbs with highly purified SARS-CoV.

The positive and preimmune control sera were from the corresponding immune mouse and tested at 1:2000 dilution in TBS + 0.2% BSA. Lanes marked 1 were loaded with highly purified SARS-CoV, lanes marked 2 with infected Vero cell lysate. The molecular weights of the pre-stained kaleidoscope markers (BioRAD) are indicated on the left of the figure.

Berry, J. D., Jones, S., Drebot, M. A., Andonov, A., Sabara, M., Yuan, X. Y., ... & Nicolas, B. (2004). Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus. Journal of virological methods, 120(1), 87-96.